Cell Based Assays Market - Global Forecast to 2033

The new report published by The Business Research Company, titled ""Cell Based Assays Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the cell based assays market size has grown strongly in recent years. It will grow from $24.61 billion in 2023 to $26.9 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The cell based assays market size is expected to see rapid growth in the next few years. It will grow to $41.86 billion in 2028 at a compound annual growth rate (CAGR) of 11.7%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2546&type=smp

The Imperative Shift To Predictive Cellular Models Is Fuelling Innovation In Cell-Based Assay Innovation Market
Research with cell-based arrays is increasing with evolution and there is a definite need to move to more predictive cellular models for drug discovery in order to control the last-stage drug failures. The pharmaceutical industries' need to efficiently commercialize drugs in order to overcome expensive failures in the last stages is a driving force in cell-based assay innovation. Failure of investigational new drug (IND) Phase III clinical trials results in a loss of several hundred million dollars to that company. For instance, according to a report by Sigma, the return on investment for pharmaceutical companies could drop to 5% considering the current level of late-stage failures which is an unacceptable level for most companies. Major improvements to high-content systems and data analysis from the cell-based assays enable scientists to extract more information about the cellular response and help make informed decisions during drug discovery, and further driving the growth of the cell-based array market.

Harnessing Early Predictive Toxicity Testing To Streamline Drug Development Costs
Researchers are inclining toward early-phase predictive toxicity testing that prevents late-stage drug failures. Predictive cell toxicity assays are being scaled up to increase the screening of compounds in the early phases of drug development, reducing the cost of failure. For instance, Creative Bioarray, a biotech company provides a range of in vitro toxicity services to check drug-induced toxicities that save time and cost by reducing the chance of failure in earlier stages. These advances will make clinical testing easy and reduce the cost of operation.

The cell based assays market covered in this report is segmented -

1) By Product & Service: Consumables, Instruments, Services, Software
2) By Technology: Automated Handling, Flow Cytometry, Label-Free Detection, High-Throughput Screening, Other Technologies
3) By Application: Drug Discovery, Basic Research, Adme Studies, Predictive Toxicology, Other Applications
4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Government Research Institutes, Contract Research Organizations (CRO), Other End Users

Sub-segements
By Instruments: Microplates, Microplate Readers, High Throughput Screening, Liquid Handling Systems
By Consumables: Reagents And Media, Cells And Cell Lines, Probes And Labels

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=2546&type=discount

Major companies operating in the cell based assays market report are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, GE HealthCare Technologies Inc., Corning Incorporated, Lonza Group Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Sigma-Aldrich Corporation, Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam plc, BioVision Inc., Promega Corporation, Caliper Life Sciences Inc., Cell Signaling Technology Inc., BioTek Instruments Inc., Enzo Life Sciences Inc., BioAgilytix Labs LLC, Cisbio International LLC, ProQinase GmbH, QGel SA, Biotium Inc., Selexis SA, Aurelia Bioscience Ltd., Creative Bioarray, Cell Biolabs Inc., Essen BioScience Ltd., Eurofins Scientific SE, DiscoveRx Corporation

Contents of the report:
1. Executive Summary
2. Cell Based Assays Market Report Structure
3. Cell Based Assays Market Trends And Strategies
4. Cell Based Assays Market - Macro Economic Scenario
5. Cell Based Assays Market Size And Growth
…..
27. Cell Based Assays Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.